Year-End Report 2024/2025
Summary
Biovica reports its 2024/2025 year-end results and highlights continued progress for DiviTum TKa, its blood-based biomarker assay for monitoring cancer treatment response. The company expands commercial partnerships with Eurobio Scientific, Tempus, and a major US healthcare and insurance organization to widen adoption in Europe and the US. Biovica also strengthens its pharma services business through multiple MSAs and new orders, while it raises capital through a directed share issue and a later rights issue. The report emphasizes growing clinical evidence, expanded market access, and rising sales momentum.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected